Back
covid-19 News
1 min de lecture

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

  • contact@xenothera.com
  • Auteur
    contact@xenothera.com
  • Publié
    11 mars 2022

Articles récents

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

More

[Newsletter] XENONEWS

June 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

More